Single-agent rituximab for primary CNS lymphoma during pregnancy as a bridge to definitive management

J Clin Oncol. 2014 Mar 1;32(7):e14-7. doi: 10.1200/JCO.2012.47.6994. Epub 2014 Jan 6.
No abstract available

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biopsy
  • Brain / pathology*
  • Carmustine / administration & dosage
  • Central Nervous System Neoplasms / diagnosis
  • Central Nervous System Neoplasms / drug therapy*
  • Cesarean Section
  • Cytarabine / administration & dosage
  • Dexamethasone / administration & dosage
  • Drug Administration Schedule
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / diagnosis
  • Lymphoma, Large B-Cell, Diffuse / drug therapy*
  • Magnetic Resonance Imaging
  • Melphalan / administration & dosage
  • Methotrexate / administration & dosage
  • Podophyllotoxin / administration & dosage
  • Pregnancy
  • Pregnancy Complications, Neoplastic / diagnosis
  • Pregnancy Complications, Neoplastic / drug therapy*
  • Pregnancy Outcome
  • Rituximab
  • Transplantation, Autologous
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Cytarabine
  • Rituximab
  • Dexamethasone
  • Podophyllotoxin
  • Melphalan
  • Carmustine
  • Methotrexate

Supplementary concepts

  • BEAM protocol